leadf
logo-loader
viewBenchmark Holdings PLC

Benchmark Holdings says European Medicine Agency committee recommends inclusion of BMK08's active pharmaceutical ingredient in fin fish

The aquaculture biotechnology business noted that this is an important step towards the launch of BMK08 together with the company's water purification system CleanTreat in the second quarter of its financial year to end-September 2021

Salmon

Benchmark Holdings PLC (LON:BMK) has revealed that the European Medicine Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) has adopted an opinion recommending the inclusion of BMK08's active pharmaceutical ingredient in fin fish as an allowed substance regarding maximum residue limits (MRL) in foodstuffs of animal origin.

The aquaculture biotechnology business noted that the MRL opinion is an important step towards the launch of BMK08 together with the company's water purification system CleanTreat in the second quarter of its financial year to end-September 2021.

READ: Benchmark swings to positive earnings in third quarter, boosted by genetics division

It pointed out that the MRL opinion is without prejudice to the European Commission's decision and ratification into EU law, which represents the next milestone for BMK08 together with CleanTreat, and is a condition for obtaining Marketing Authorisation (MA) in Norway.

In a statement, Trond Wiliksen, Benchmark’s CEO commented: "The MRL opinion is a significant stepping stone towards the launch of our novel sea lice treatment BMK08, together with CleanTreat which purifies the treatment water. The positive opinion of the European Medicine Agency's experts in medicine safety is a critical step in a 10-year data collection and assessment process which ensures that the medicine is safe to use and safe for consumers."

 "I congratulate our teams for getting us to this point and we look forward to making further progress towards a launch in Q2 CY 2021," he added.

Quick facts: Benchmark Holdings PLC

Price: 44 GBX

AIM:BMK
Market: AIM
Market Cap: £293.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Benchmark Holdings PLC named herein, including the promotion by the Company of Benchmark Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Benchmark Holdings 'moving towards being a streamlined and profitable company'

Benchmark Holdings PLC's (LON:BMK) Trond Williksen and Septima Maguire caught up with Proactive to discuss its third quarter results. The firm posted positive earnings in the period, which it attributed to higher revenues and margins in its genetics division after moving external production...

4 weeks ago

2 min read